FMP
Nov 19, 2025
Nanox Imaging Ltd (NASDAQ:NNOX) is a company that specializes in innovative medical imaging technology. They are set to release their quarterly earnings on Thursday, November 20, 2025. Wall Street anticipates an earnings per share (EPS) of -$0.175 and a revenue of approximately $3.5 million. This release will provide insights into the company's financial health and operational performance.
Nanox recently announced an agreement to acquire VasoHealthcare IT Inc. from Vaso Corporation. This acquisition aims to accelerate the rollout of Nanox's AI solutions in U.S. healthcare facilities. VasoHealthcare IT specializes in healthcare information technology services, including systems integration and workflow optimization. The transaction is expected to close in a few weeks, pending certain conditions.
Despite a negative price-to-earnings (P/E) ratio of -3.49, NNOX is experiencing financial challenges. The price-to-sales ratio of 16.35 indicates that investors are paying $16.35 for every dollar of sales. This suggests that investors have high expectations for the company's future growth, despite current earnings difficulties.
The enterprise value to sales ratio of 12.82 reflects the company's valuation relative to its sales. However, the enterprise value to operating cash flow ratio of -3.98 highlights negative operating cash flow. This indicates that the company is currently not generating positive cash flow from its operations, which can be a concern for investors.
NNOX has a debt-to-equity ratio of 0.05, indicating a low level of debt compared to equity. This suggests that the company is not heavily reliant on debt financing. Additionally, the current ratio of 4.19 shows that NNOX has a strong liquidity position, meaning it can cover its short-term liabilities with its current assets.
In the recent market analysis, several companies have emerged as top losers, experiencing significant price drops. Medic...
INOVIO Pharmaceuticals, trading on NASDAQ under the symbol INO, is a biotechnology company focused on developing DNA med...